Company news

Mesoblast Limited news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

FDA Approves New Potency Assay for Commercial Ryoncil

September 23, 2026

Annual Report for Fiscal Year Ending June 30, 2026 (Form 20-F)

August 27, 2026

Mesoblast Reports Substantial Revenue Growth to US$120M

August 26, 2026

Major Milestone Treatment Completed in P3 Trial for CLBP

August 16, 2026

Mesoblast Reports Ryoncil® Net Revenues of US$36M for the Quarter and US$115M for First Full Year of Product Launch

July 28, 2026

Mesoblast Achieves Target of 300 Treated Patients in Pivotal Phase 3 Trial for Chronic Low Back Pain

July 13, 2026

Pivotal Phase 3 Trial in CLBP Achieves 300 Treated Patients

July 13, 2026

Ryoncil® Delivers Net Revenue of US$36M for the Fourth Quarter Ended 30 June 2026

July 9, 2026

Ryoncil Q4 Net Revenue of US$36M and US$115M for Full Year

July 9, 2026

Mesoblast Draws US$50M from Five-Year Non-Dilutive Facility

June 24, 2026

Mesoblast Reports Ryoncil® Net Revenues of US$30.3m and Improved Net Operating Cash Spend for the Quarter to US$4.1 Million

April 28, 2026

Patient Recruitment Target Achieved in CLBP Pivotal Trial

April 29, 2026

Mesoblast Achieves Patient Recruitment Target in Pivotal Phase 3 Trial for Chronic Low Back Pain

April 28, 2026

Mesoblast Acquires Chimeric Antigen Receptor (CAR) Platform Technology for Precision-Enhanced Cell Products

April 14, 2026

Mesoblast Receives IND Clearance From FDA to Directly Proceed to Registrational Trial for Approval of Ryoncil® in Duchenne Muscular Dystrophy - CORRECTION

April 10, 2026

Mesoblast R&D Day Features Significant Commercial Progress & Platform Innovation

April 8, 2026

Mesoblast Receives IND Clearance from FDA to Directly Proceed to Registrational Trial for Approval of Ryoncil® in Duchenne Muscular Dystrophy

April 6, 2026

Ryoncil Net Revenue for the Quarter Increases to US$30.3M

April 7, 2026

Ryoncil® Continues Successful First Year Launch with Net Sales of US$30.3M in March Quarter

April 5, 2026

Mesoblast to Host R&D Day on April 8, 2026

March 17, 2026

Dr. Teresa Montagut Appointed as Clinical Development and Medical Affairs Head at Mesoblast

March 11, 2026

Ryoncil Profits Underpinning Substantial Growth Pipeline

February 26, 2026

Corporate Presentation and Half Year Financial Results

February 26, 2026

Half Year Report and Accounts (including Appendix 4D)

February 26, 2026

Ryoncil® Profits Underpinning Substantial Growth Pipeline

February 26, 2026

High Survival Rates With Ryoncil® in EIND Program Emphasize Importance of Earlier Use in Both Children and Adults With SR-aGvHD

February 11, 2026

Quarterly Activities/Appendix 4C Cash Flow Report

January 28, 2026

Ryoncil® Net Revenues Increase for the Quarter to US$30M

January 28, 2026

Real-World Commercial Experience with Ryoncil® Shows 84% Survival of Children with SR-aGvHD After Completing 28-Days of Treatment

January 26, 2026

FDA Acknowledges Effects on Pain Intensity Favor Rexlemestrocel-L, Confirms 12-Month Reduction in Back Pain Supports Product Efficacy

January 17, 2026

Ryoncil Sales for the Quarter Increase 60% to US$35.1M

January 8, 2026

Ryoncil® Sales Increase 60% in December Quarter to US$35.1M

January 8, 2026

Mesoblast Announces Changes to Board of Directors' Leadership Roles

January 1, 2026

Mesoblast Enters into Non-Dilutive Lower Cost 5-Year Credit

December 29, 2025

Mesoblast Retires Senior Debt with Non-Dilutive, Lower Cost, Five-Year Credit Line

December 29, 2025

Independent Study Presented at American Society of Hematology (ASH) Annual Meeting Concludes Remestemcel-L Superior to Ruxolitinib in Clinical Outcomes as Treatment for SR-aGvHD

December 11, 2025

Mesoblast Participation at Piper Sandler Conference

December 3, 2025

Cadrenal Therapeutics Appoints Dr. Lee Golden to Board of Directors

December 1, 2025

Ryoncil Revenue Growth Highlighted in AGM Trading Update

November 24, 2025

CEO Presentation to 2025 Annual General Meeting

November 24, 2025

Mesoblast Trading Update at Annual General Meeting Highlights Continued Strong Growth in Ryoncil® Revenue

November 24, 2025

Mesoblast and BMT CTN to Initiate Pivotal Trial of Ryoncil® as Part of First-Line Regimen in Adults with Severe Acute GVHD Refractory to Steroids

November 20, 2025

James M. O’Brien Appointed Chief Financial Officer at Mesoblast

November 17, 2025

Mesoblast to Meet With FDA Next Month to Discuss Rexlemestrocel-L and Opioid Cessation

November 4, 2025

Ryoncil® Net Revenues Increase 69% in Second Quarter Post Launch

October 19, 2025

Ryoncil Revenues Increase 66% in Second Quarter Post Launch

October 6, 2025

Ryoncil® Revenues Increase 66% in Second Quarter Post Launch

October 6, 2025

Ryoncil® Receives J-Code From Medicare & Medicaid Services (CMS) Facilitating Reimbursement and Broader Patient Access

October 2, 2025

Mesoblast Cell Therapy Products are Designated U.S. Origin and Not Subject to Tariffs

September 26, 2025

Successful Commercial Launch of Ryoncil® Highlighted at Global Healthcare Conferences

September 14, 2025

Older news releases →

Calls

The 5 newest of 10 calls. Every call is listed under its year.

Decks

The 5 newest of 105 decks. Every deck is listed under its year.